You can buy or sell ImmunoGen and other stocks, options, ETFs, and crypto commission-free!
ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. Read More The company was founded in March 1981 and is headquartered in Waltham, MA. The listed name for IMGN is ImmunoGen, Inc. Common Stock.
52 Week High
52 Week Low
— per share
Expected Oct 30, Pre-Market